Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.80 |
| ▸ | RET | P07949 | 4/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.66 |
| ▸ | FLT3 | P36888 | 3/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.66 |
| ▸ | FLT1 | P17948 | 3/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | FLT4 | P35916 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117305 | 1.00 | KDR (0.80) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL5465253 | 0.89 | KDR (1.00) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL5465247 | 0.89 | KDR (1.00) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL2114209 | 0.87 | KDR (0.73) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL2114210 | 0.87 | KDR (0.73) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL31672504 | 0.87 | KDR (0.73) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL5469611 | 0.85 | KDR (0.81) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL5469616 | 0.85 | KDR (0.81) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL14448819 | 0.84 | KDR (0.67) | KDRRETFGFR1FLT3ALK | |
| SCHEMBL5202974 | 0.82 | KDR (0.63) | KDRRETFGFR1FLT3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259234-B9 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1259234-B1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2006-08-16 | — | — | EP | claimed |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | SUGEN INC. | 2003-10-09 | — | — | US | claimed |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. | 2003-04-17 | — | — | US | claimed |
| EP-1259234-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | claimed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010120387-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-1259234-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1139754-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | Sugen, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000038519-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | KDR 648/4885RET 355/4885FGFR1 48/4885 |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | DCK, TNK2, MKNK1 | KDR 2091/4885RET 882/4885FGFR1 1576/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885RET 73/4885FGFR1 462/4885 |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | DCK, TNK2, MKNK1 | KDR 2091/4885RET 882/4885FGFR1 1576/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | KDR 1372/4885RET 485/4885FGFR1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.